Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma: ctDNA and MRD in pancreatic adenocarcinoma

Benjamin E. Ueberroth, Jeremy C. Jones, Tanios S. Bekaii-Saab

Research output: Contribution to journal › Review article › peer-review

Fingerprint

Dive into the research topics of 'Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma: ctDNA and MRD in pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences